2021-003405-22: Research study to assess the potential of masupirdine in patients with agitation symptoms associated with memory loss |
|
|
| Ongoing | 3 | 375 | Europe, RoW | Masupirdine, SUVN-502, Tablet | Suven Life Sciences Ltd., Suven Life Sciences Ltd | Agitation with Dementia of the Alzheimer's Type, Agitation symptoms associated with memory loss, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Recruiting | 3 | 375 | Europe, US, RoW | Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo | Suven Life Sciences Limited, Suven Life Sciences Ltd | Agitation, Alzheimer's Type Dementia | 01/25 | 01/25 | | |
